PharmaCyte Biotech, Inc. (PMCB)

Nasdaq: PMCB · Biological Products, (No Diagnostic Substances) · Las Vegas, NV · filing with the SEC since 2001

Full chart Alerts Compare

Grade4.8

◀ Past 7.0● Present 4.6▶ Future 3.7

4 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of PharmaCyte Biotech, Inc.

Nine metrics read from its own filings, by tense

Headline grade

4.8/10

◀ Past7.025% of the headline

● Present4.635% of the headline

▶ Future3.740% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 5 read as filed from the record and 4 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.0/1025% of the headline grade · 3 of 3 filed

Surviving crises

as filed

0.6/10

Has it survived what it has been through?

16 warning events since 2017; the latest 2026-10-16.

weight 22% of this tense · 6th percentile among 159 sector filers · read for itself

From the record

PharmaCyte Biotech, Inc.'s filings since 2017 show 16 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2025-12-05); an auditor change (8-K item 4.01, 4 times, the latest 2026-10-16); a late-report notice (Form NT 10-K or NT 10-Q, 9 times, the latest 2025-12-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

8.3/10

What has it actually done, year after year?

10 filed years; profitable in 2 of 10.

weight 45% of this tense · 83rd percentile among 102 sector filers · read for its customers

From the record

PharmaCyte Biotech, Inc.'s 10 filed years say what it did: it never fell from a peak; net income was positive in 2 of 10 of those years (its annual reports).

What it rests on

the share of filed years with a profittop 25% of its family
the deepest fall from a revenue peak0.0%top 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

as filed

9.5/10

How has it treated the people who own it?

Share count shrank 24.5% a year. 100% of cash flow returned. Insiders: 0 sales, 6 purchases.

weight 33% of this tense · 95th percentile among 21 sector filers · read for its shareholders

From the record

Over the 3 fiscal years to 2026-04-30, PharmaCyte Biotech, Inc.'s diluted share count shrank about 24.5% a year, and dividends and buybacks returned about 100% of its net income over 3 years (its filed statements). Its officers and directors filed 0 sales and 6 purchases of their own stock on the open market in the year to 2026-09-30, buying about $129 thousand (their Form 4 filings).

What it rests on

the share count over the yearstop 3% of its family
cash returned against operating cash flowtop 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

● Present

What are they doing right now?

4.6/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

5.4/10

Is it financially healthy right now?

ROE -58%: lost 58¢ per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar.

weight 45% of this tense · 54th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2026-04-30, PharmaCyte Biotech, Inc. lost about 58 cents for every dollar of shareholders' money. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 14.3% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 40% of its family
return on equitybottom 48% of its family
the share count against the year beforetop 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

SI estimate

4.9/10

How strong is its position in its industry?

SI estimate 4.9/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 102 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: No filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 102 members with one.
What the record cannot read: No filed revenue on file.
How it was reasoned: family median, 102 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: PharmaCyte Biotech, Inc.'s industry position is put at 4.9 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 102 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

Leadership

as filed

3.4/10

What are the people in charge doing?

bottom 34% of 110 in its family for leadership; chief executive since 2023.

weight 33% of this tense · 34th percentile among 110 sector filers · read for its shareholders

From the record

PharmaCyte Biotech, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Silverman, Joshua (CEO and President, as filed), filing under that title since 2023-11-22, 3 years (bottom 34% of its family); most of the 5 officers and directors filing now have filed since the record of its people begins (2022-08-23), a floor of 4.2 years the record cannot see past, so that part is not read; 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 5 people in charge now (bottom 35%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge3 in three years among 5 peoplebottom 35% of its family
the chief executive's years on the record3.0 yearsbottom 34% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

3.7/1040% of the headline grade · 0 of 3 filed, 3 estimated

Room to expand

SI estimate

6.0/10

How much room does it have to grow?

SI estimate 6.0/10, confidence 35 of 100 (one part).

weight 33% of this tense · 60th percentile among 152 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, cash less debt against assets, which ranks in the top 40% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: one part: cash less debt against assets, the one part on file, ranked among 152 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: PharmaCyte Biotech, Inc.'s room to expand is put at 6.0 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 40% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

SI estimate

3.5/10

What could actually drive growth from here?

SI estimate 3.5/10, confidence 35 of 100 (one part).

weight 45% of this tense · 35th percentile among 102 sector filers · read for its customers

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the three-year growth of research spending, which ranks in the bottom 35% of 102 in its family; the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
What the record cannot read: The record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending.
How it was reasoned: one part: three-year growth of research spending, the one part on file, ranked among 102 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: PharmaCyte Biotech, Inc.'s growth drivers is put at 3.5 of 10 with a confidence of 35 of 100, because read from one part only, the three-year growth of research spending, which ranks in the bottom 35% of 102 in its family; the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending. A filing that carries the missing parts replaces this estimate with the filed reading.

Expectations vs reality

SI estimate

0.6/10

Did its newest year beat what its own record pointed to?

SI estimate 0.6/10, confidence 35 of 100 (one part).

weight 22% of this tense · 6th percentile among 90 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, net income against the prior three years' average, which ranks in the bottom 6% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: one part: net income against the prior three years' average, the one part on file, ranked among 90 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: PharmaCyte Biotech, Inc.'s expectations vs reality is put at 0.6 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 6% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PMCB · research, not advice